In contrast, the “Albumin for the Treatment of Ascites in Patients with Hepatic Cirrhosis” (ANSWER) [45] RCT and the smaller Pilot-PRECIOSA and INFECIR-2 studies have reported various benefits, most crucially for overall patient outcomes. The gene discussed is ALB; the disease is Cirrhosis.